H. Lundbeck Investor Relations Material
Latest events
Q1 2025
H. Lundbeck
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from H. Lundbeck
Access all reports
H. Lundbeck A/S develops, manufactures, and sells pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, the United States, Canada, and internationally. The company offers psychiatric products, including Abilify Maintena for maintenance treatment of adults with bipolar I disorder or schizophrenia; Risperdal Consta for maintenance treatment of schizophrenia; Vraylar/Lenvima/Xalkori for treating schizophrenia in various countries; Brintellix/Trintellix for treating major depressive disorder; and Rexulti/Brexiprazole as adjunctive therapy with antidepressants in treating adult patients with major depressive disorder. The company was founded in 1915 and is headquartered in Valby, Denmark.
Key slides for H. Lundbeck
Q1 2025
H. Lundbeck
Q1 2025
H. Lundbeck
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
LUN
Country
🇩🇰 Denmark